Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Papakosta (Thessaloniki, Greece), S. Loukides (Athens, Greece), K. Katsoulis (Thessaloniki, Greece), E. Zervas (Athens, Greece), K. Apostolidou (Attica, Greece), M. Bertoli (Attica, Greece), A. Ginis (Attica, Greece), P. Bakakos (Athens, Greece). Asthma control and quality of life in asthmatic patients treated for 6 months with FDC Budesonide/Formoterol - BOREAS study: a subgroup analysis in patients with comorbidities. 2568

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of asthma control and quality of life after 6 months of treatment with FDC Budesonide/Formoterol-BOREAS study. Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Quality of life and symptoms improvement after 6 months treatment with roflumilast 500 μg daily in a large Greek COPD cohort Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013 Evaluation of quality of life (QOL) in asthma patients during 6 months formoterol therapy Source: Eur Respir J 2001; 18: Suppl. 33, 44s Year: 2001 Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Economic evaluation of eformoterol compared with salmeterol in children aged 6-17 years with symptomatic asthma in the UK: cost-effectiveness results of the FACT study Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001 Asthma control and COPD symptom burden: results from a multi-country observational study (SPRINT) in patients using fixed dose combination (FDC) inhalers Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 Direct cost analysis of COPD patients: A 1 year follow-up study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Health related quality of life in asthmatic subjects after 3 months treatment with inhaled corticosteroids Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Long-term (4 years) experience of Nintedanib in IPF patients in Crete: A real life data study Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Patients’ evaluation on asthma severity was related to level of asthma control and quality of life over seven years follow-up Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study) Source: Eur Respir J , 49 (3) 1501885; DOI: 10.1183/13993003.01885-2015 Year: 2017 Lung function evaluation and patients’ satisfaction with Elpenhaler® device in Greek COPD patients with =1 comorbidity versus patients without comorbidities-AEOLOS study. Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Four years follow-up of exacerbations in a cohort of COPD patients: 1 year interim results (EXACO study) Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Assessment of quality of life in asthmatic children. A case- control study Source: Annual Congress 2012 - Assessing and treating childhood asthma and allergy Year: 2012 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Change of COPD maintenance medication over two years in a large real life cohort: The DACCORD study Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Exacerbations in a cohort of COPD patients: frequent exacerbators characteristics after 1-year follow-up (EXACO study – interim analysis) Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013